Uncategorized
Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to RhopressaTM in their Tampa, Florida facility will not be ready for pre-approval inspection by the FDA until the en